Compounds > nemonoxacin

Page last updated: 2024-11-12

nemonoxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nemonoxacin: has antibacterial activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11993740
CHEMBL ID	1213456
CHEBI ID	136053
SCHEMBL ID	1006373
MeSH ID	M0539102

Synonyms (26)

Synonym
CHEMBL1213456
CHEBI:136053
nemonoxacin
tg-873870
p94l0pvo94 ,
tg873870
tg 873870
nemonoxacin [inn]
378746-64-6
unii-p94l0pvo94
SCHEMBL1006373
3-quinolinecarboxylic acid, 7-((3s,5s)-3-amino-5-methyl-1-piperidinyl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-
nemonoxacin [who-dd]
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- oxo-1,4-dihydroquinoline-3-carboxylic acid
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
7-((3s,5s)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
DB06600
Q15425793
gtpl10836
7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic acid
MS-25985
DTXSID10958907
TQP0855
HY-14956
CS-0003656
STARBLD0028467

Research Excerpts

Overview

Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens. It has strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare.

Excerpt	Reference	Relevance
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus, penicillin- and quinolone-resistant Streptococcus pneumoniae, and vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. "	( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010)	2.03
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with broad-spectrum activities against Gram-positive and Gram-negative aerobic, anaerobic, and atypical pathogens, as well as against methicillin-resistant Staphylococcus aureus, vancomycin-resistant S. "	( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010)	2.04
"Nemonoxacin is a novel non-fluorinated quinolone with strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare. "	( Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chen, Y; Li, Z; Meng, W; Xiong, R; Zeng, H; Zhao, Z, 2023)	3.8
"Nemonoxacin is a nonfluorinated quinolone with good bactericidal effects against quinolone-resistant Gram-positive microorganisms. "	( Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan. Chang, LW; Cheng, A; Hsu, MC; Sheng, WH; Tai, HM; Yang, JJ, 2020)	2.32
"Nemonoxacin is a novel non-fluorinated quinolone. "	( Nemonoxacin Has Immunoprotective Effects on Reducing Mortality in Lipopolysaccharide-Induced Mouse Sepsis Model. Chen, N; Feng, M; Guo, B; Huang, J; Li, X; Lin, D; Zhao, X; Zou, J, 2020)	3.44
"Nemonoxacin is a novel nonfluorinated quinolone with excellent in vitro activity against most pathogens in community-acquired pneumonia (CAP), especially Gram-positive isolates. "	( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019)	2.25
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone that has been approved for the treatment of community-acquired pneumonia (CAP) in adults. "	( Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Chen, Y; Guo, B; Kang, Y; Li, Y; Wang, K; Wu, J; Xu, F; Yu, J; Zhang, J; Zhang, Y, 2019)	2.23
"Nemonoxacin is a novel C-8-methoxy nonfluorinated quinolone with remarkably enhanced in vitro activity against a wide variety of clinically relevant pathogens, especially gram-positive bacteria, including multidrug-resistant Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus. "	( Review of nemonoxacin with special focus on clinical development. Huang, H; Qin, X, 2014)	2.25
"Nemonoxacin (TG-873870) is a novel nonfluorinated quinolone with potent broad-spectrum activity against Gram-positive, Gram-negative, and atypical pathogens, including vancomycin-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA), quinolone-resistant MRSA, quinolone-resistant Streptococcus pneumoniae, penicillin-resistant S. "	( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers. Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014)	2.09
"Nemonoxacin (TG-873870) is a novel C-8-methoxy nonfluorinated quinolone with higher activity than ciprofloxacin, levofloxacin and moxifloxacin against Gram-positive pathogens including methicillin-susceptible or methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae with various resistant phenotypes. "	( A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Guo, B; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2012)	2.05

Effects

Excerpt	Reference	Relevance
"Nemonoxacin has a sound PK profile in healthy volunteers."	( Review of nemonoxacin with special focus on clinical development. Huang, H; Qin, X, 2014)	1.53
"Oral nemonoxacin has been approved in Taiwan for the treatment of CAP in adults."	( Nemonoxacin: first global approval. Poole, RM, 2014)	2.3

Actions

Excerpt	Reference	Relevance
"Nemonoxacin showed lower MICs against clinical C."	( The potential role of nemonoxacin for treatment of common infections. Chen, YH; Hsueh, PR; Huang, CH; Lai, CC, 2015)	1.45

Toxicity

Nemonoxacin was generally safe and well tolerated, with no significant changes in the clinical laboratory tests or electrocardiograms. The incidence of adverse events (AEs) was comparable between nemonxacin (33%) and levofloxacins (33%).

Excerpt	Reference	Relevance
" No severe or serious adverse events were observed."	( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010)	0.59
" Nemonoxacin was generally safe and well tolerated, with no significant changes in the clinical laboratory tests or electrocardiograms."	( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010)	1.51
" All three treatments were well tolerated, and no drug-related serious adverse events were observed."	( Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia. Bester, AJ; Chang, LW; Chang, YT; Chung, DT; Ho, ML; Hsu, MC; Kasumba, J; King, CH; Mitha, IH; Perng, RP; van Rensburg, DJ; Wu, RG, 2010)	0.67
"No severe or serious adverse events (AEs) occurred in this study, and no clinically significant abnormalities were noted in the vital signs or on physical examination."	( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012)	0.65
" Drug-related adverse events (AEs) were mild, transient, and confined to local irritation at the injection site."	( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers. Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014)	0.65
" Most drug-related adverse events were mild and transient, mainly gastrointestinal symptoms such as nausea and vomiting, transient neutropenia, and elevated liver enzymes."	( A randomized, double-blind, multicenter Phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia. Cao, Z; Chang, L; Chen, P; Cui, S; Hu, C; Kuang, J; Li, J; Liang, Y; Liu, H; Liu, S; Liu, Y; Lv, X; Lv, Y; Ren, Z; Sun, S; Wang, C; Wang, D; Wang, X; Wu, J; Xiao, Z; Xiu, Q; Yang, H; Zhang, Y; Zhao, L; Zhu, D, 2017)	0.67
" Clinical, microbiological response and adverse events were assessed."	( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019)	0.81
" The incidence of adverse events (AEs) was comparable between nemonoxacin (33."	( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019)	1.05
"Nemonoxacin 500 mg once daily for 7-10 days is as effective and safe as levofloxacin for treating adult CAP patients in terms of clinical cure rates, microbiological success rates, and safety profile."	( Safety and efficacy of oral nemonoxacin versus levofloxacin in treatment of community-acquired pneumonia: A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, non-inferiority trial. Cao, Z; Chang, L; Cheng, SL; Lv, Y; Ma, Z; Mo, B; Sun, S; Tong, Z; Wu, J; Wu, R; Yang, Y; Yuan, J; Zhang, Y; Zhu, D, 2019)	2.25
" The incidence of adverse events (AEs) was the highest (54."	( Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia. Chang, LW; Chang, YT; Cheng, SL; Chuang, YC; Hsu, MC; Perng, WC; Tsao, SM; Wu, RG, 2019)	0.75

Pharmacokinetics

The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers. The peak time and elimination half-life of nemonoxacin were 1 to 2 h and 9 to 16 h, respectively. This first-in-human study was aimed at assessing the safety, tolerability, and pharmacokinetics properties of intravenous nemon Oxacin.

Excerpt	Reference	Relevance
" The peak time and elimination half-life of nemonoxacin were 1 to 2 h and 9 to 16 h, respectively."	( Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. Ajayi, F; Aronstein, WS; Chang, LW; Chung, DT; Hsu, CH; Kuzmak, B; Lin, L; Lyon, RA; Tsai, CY, 2010)	0.85
" The method was successfully applied to a pharmacokinetic study enrolling 12 healthy Chinese volunteers administered nemonoxacin malate capsules."	( A liquid chromatography-tandem mass spectrometry assay for the determination of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, in human plasma and urine and its application to a single-dose pharmacokinetic study in healthy Chinese volunteers. Guo, B; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2012)	0.82
" The elimination half-life was 10-12 hours."	( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012)	0.65
" When the MIC is high, the time (T) dependency is important and the valid PK/PD index should be the cumulative percentage of a 24-h period in which the drug concentration exceeds the MIC under steady-state pharmacokinetic conditions (f%T>MIC), which means that to split the maximum daily dose into several separate doses will benefit the eradication of the bacteria."	( Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model. Cao, YR; Chen, YC; Guo, QL; Hu, JL; Huang, J; Liang, W; Liu, XF; Wu, XJ; Zhang, J; Zhang, SJ; Zhang, YY; Zhao, M; Zhu, DM, 2013)	0.66
" This first-in-human study was aimed at assessing the safety, tolerability, and pharmacokinetic properties of intravenous nemonoxacin in healthy Chinese volunteers."	( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers. Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014)	0.85
" This review focuses on recent advances concerning quinolones and fluoroquinolones, we will be summarising chemical structure, mode of action, pharmacokinetic properties and toxicity."	( Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Domokos, J; Kocsis, B; Szabo, D, 2016)	0.64
" The goals of this study were to evaluate the pharmacokinetic (PK) and population PK parameters of nemonoxacin and to provide the appropriate dose adjustment recommendations for patients with hepatic impairment."	( Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Chen, Y; Guo, B; Kang, Y; Li, Y; Wang, K; Wu, J; Xu, F; Yu, J; Zhang, J; Zhang, Y, 2019)	1
"To optimize the dosing regimen in patients with severe renal impairment based on population pharmacokinetic (PPK)/pharmacodynamic analysis."	( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis. Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021)	2.06

Bioavailability

Excerpt	Reference	Relevance
" The validated methods were successfully applied to an absolute bioavailability clinical study of nemonoxacin malate capsule."	( Determination of a novel nonfluorinated quinolone, nemonoxacin, in human feces and its glucuronide conjugate in human urine and feces by high-performance liquid chromatography-triple quadrupole mass spectrometry. Cao, G; Guo, B; He, G; Shi, Y; Tsai, CY; Wu, X; Yu, J; Zhang, J, 2015)	0.89

Dosage Studied

Nemonoxacin 0.5-750 mg exhibited a linear dose-response relationship between the AUC0-72 h and A UC0-∞. PPK/pharmacodynamic modelling and simulation of 4 dosage regimens found that nemonxacin was safe to use once daily.

Excerpt	Relevance	Reference
" The maximum plasma concentration and the area under the plasma concentration-time curve were dose proportional over the dosing range."	( Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. Chang, LW; Chang, YT; Chen, SJ; Chiu, KM; Chung, DT; Hsu, CH; Hsu, MC; King, CH; Tan, HC; Tsai, CY, 2010)	0.6
" The PK and safety profiles of nemonoxacin in Chinese subjects support evaluation of once-daily dosing in the future development of this agent."	( Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses. Cao, G; Guo, B; Shi, Y; Wu, X; Yu, J; Zhang, J; Zhang, Y, 2012)	0.93
" Volunteers treated with 250 to 750 mg nemonoxacin exhibited a linear dose-response relationship between the AUC0-72 h and AUC0-∞."	( Safety, tolerability, and pharmacokinetics of intravenous nemonoxacin in healthy chinese volunteers. Cao, GY; Chen, YC; Guo, BN; Shi, YG; Wu, JF; Wu, XJ; Yu, JC; Zhang, J; Zhang, YY, 2014)	0.92
" A Monte Carlo simulation indicated that the cumulative fraction of response of any dosing regimen was nearly 100% against Streptococcus pneumoniae."	( Pharmacokinetics and pharmacodynamics of multiple-dose intravenous nemonoxacin in healthy Chinese volunteers. Cao, GY; Chang, LW; Chang, YT; Chen, YC; Guo, BN; Shi, YG; Tsai, CY; Wu, JF; Wu, XJ; Ye, XY; Yu, JC; Zhang, J; Zhang, YY; Zhu, DM, 2015)	0.65
"To optimize the dosing regimen in patients with severe renal impairment based on population pharmacokinetic (PPK)/pharmacodynamic analysis."	( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis. Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021)	2.06
"An extended dosing interval (0."	( Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis. Chen, Y; Fan, Y; Guo, B; Hu, J; Kang, Y; Li, X; Li, Y; Liu, X; Lu, J; Wang, K; Wang, Y; Wu, H; Wu, J; Xu, X; Xue, J; Yu, J; Zeng, X; Zhang, J; Zhang, Y; Zhao, M, 2021)	2.06

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
quinolines	A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (438)

Assay ID	Title	Year	Journal	Article
AID495544	Toxicity in human assessed as occurrence of somnolence at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570925	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495607	Renal clearance in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571353	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570928	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571363	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570683	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495476	Clearance in healthy human assessed as recovery of unchanged drug in urine at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570685	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571359	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571361	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570696	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495433	Cmax in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495578	Terminal half life in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495537	Toxicity in human assessed as occurrence of diarrhea at 1000 mgkg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495787	Cmax in human at 500 mg/kg, po measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570668	Antibacterial activity against Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495482	Antimicrobial activity against penicillin-sensitive Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495388	Toxicity in healthy human assessed as occurrence of headache at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570701	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570708	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495387	Toxicity in healthy human assessed as occurrence of headache at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495424	Toxicity in healthy human assessed as occurrence of ear pain at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570694	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495463	Clearance in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570664	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495472	Renal clearance in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570665	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495494	Ratio of fAUC to MIC90 for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570675	Antibacterial activity against Stenotrophomonas maltophilia by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571381	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571382	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570687	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495533	Toxicity in human assessed as occurrence of pruritus at 750 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495577	Terminal half life in human at 750 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570917	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570901	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570702	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495611	Renal clearance in human at 1000 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571366	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495465	Clearance in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571141	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495442	Tmax in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570688	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571358	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495455	Terminal volume of distribution in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495584	Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 1 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570909	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495471	Renal clearance in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495569	AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495610	Renal clearance in human at 750mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495528	Toxicity in human assessed as occurrence of abdominal pain at 750 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495621	AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571848	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495591	Clearance in human assessed as compound recovered in urine at 1000 mg/kg, po measured on day 1 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571869	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495419	Toxicity in healthy human assessed as occurrence of ear pain at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495623	AUC(0 to last) in human at 500 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495572	AUC (0 to last) in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495499	Ratio of fCmax to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495403	Toxicity in healthy human assessed as occurrence of abdominal pain at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570706	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571881	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495556	Tmax in human at 75 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570918	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495604	Renal clearance in human at 250 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570898	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570920	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495429	AUC (0 to infinity) in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570921	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495583	Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 10 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495441	Tmax in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570900	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495600	Oral clearance in human at 1000 mg/kg measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495573	AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495428	AUC (0 to infinity) in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571878	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495647	Toxicity in healthy human assessed as occurrence of erythema at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570705	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495530	Toxicity in human assessed as occurrence of pruritus at 75 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571843	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495480	Clearance in healthy human assessed as recovery of unchanged drug in urine at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495439	Tmax in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495567	Tmax in human at 1000 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571850	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571847	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570899	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495532	Toxicity in human assessed as occurrence of pruritus at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495400	Toxicity in healthy human assessed as occurrence of abdominal pain at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571345	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571844	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495401	Toxicity in healthy human assessed as occurrence of abdominal pain at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495421	Toxicity in healthy human assessed as occurrence of ear pain at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570896	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495627	Plasma protein binding in human	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495602	Renal clearance in human at 75 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495523	Toxicity in human assessed as occurrence of rashes at 75 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571867	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570697	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570927	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495431	AUC (0 to infinity) in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495538	Toxicity in human assessed as occurrence of pollakiuria at 75 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571842	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570672	Antibacterial activity against Enterococcus faecium by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495366	Toxicity in healthy human assessed as occurrence of contact dermatitis at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495481	Antimicrobial activity against Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571841	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495405	Toxicity in healthy human assessed as occurrence of pustular rashes at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495468	Renal clearance in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495617	AUC (0 to 24 hrs) in human at 750 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570667	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571130	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495413	Toxicity in healthy human assessed as occurrence of nausea at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495497	Ratio of fCmax to MIC90 for penicillin-intermediate Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495727	Clearance in healthy human assessed as recovery of unchanged drug in urine at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570690	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495615	AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571365	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570916	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495450	Terminal phase elimination half-life in healthy human at 500 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570671	Antibacterial activity against Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571380	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571342	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495483	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495469	Renal clearance in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495380	Toxicity in healthy human assessed as occurrence of erythema at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495460	Clearance in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495399	Toxicity in healthy human assessed as occurrence of abdominal pain at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495566	Tmax in human at 750 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570923	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495500	Ratio of fCmax to MIC90 for methicillin-sensitive Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570932	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495599	Oral clearance in human at 500 mg/kg measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571118	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495601	Oral clearance in human at 1000 mg/kg measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495521	Toxicity in human assessed as occurrence of dermatitis at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495575	AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495394	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495432	Cmax in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495410	Toxicity in healthy human assessed as occurrence of pustular rashes at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495570	AUC (0 to last) in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495435	Cmax in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495488	Ratio of fAUC to MIC90 for Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495559	AUC (0 to 24 hrs)in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571853	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571836	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570929	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495589	Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 1 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495562	Tmax in human at 500 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571862	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of >=512 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495588	Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 16 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571852	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495526	Toxicity in human assessed as occurrence of abdominal pain at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495375	Toxicity in healthy human assessed as occurrence of pruritus at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495603	Renal clearance in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495364	Toxicity in healthy human assessed as occurrence of contact dermatitis at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495495	Ratio of fCmax to MIC90 for Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571860	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495367	Toxicity in healthy human assessed as occurrence of contact dermatitis at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495557	Tmax in human at 250 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495417	Toxicity in healthy human assessed as occurrence of nausea at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570887	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495420	Toxicity in healthy human assessed as occurrence of ear pain at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570926	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495436	Cmax in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495427	AUC (0 to infinity) in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495440	Tmax in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571348	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571338	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570676	Antibacterial activity against Acinetobacter baumannii by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571370	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495386	Toxicity in healthy human assessed as occurrence of headache at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571343	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495371	Toxicity in healthy human assessed as occurrence of pruritus at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495408	Toxicity in healthy human assessed as occurrence of pustular rashes at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495586	Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 1 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495498	Ratio of fCmax to MIC90 for penicillin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495598	Oral clearance in human at 500 mg/kg measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495594	Oral clearance in human at 75 mg/kg measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495383	Toxicity in healthy human assessed as occurrence of headache at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495574	AUC (0 to last) in human at 750 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495612	Renal clearance in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495529	Toxicity in human assessed as occurrence of abdominal pain at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495553	Cmax in human at 750 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495422	Toxicity in healthy human assessed as occurrence of ear pain at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495585	Clearance in human assessed as compound recovered in urine at 250 mg/kg, po measured on day 10 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495605	Renal clearance in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495596	Oral clearance in human at 250 mg/kg measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570700	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571105	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570905	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495437	Cmax in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495398	Toxicity in healthy human assessed as occurrence of abdominal pain at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495625	Oral clearance in human at 750 mg/kg measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571347	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570906	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571351	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495501	Ratio of fCmax to MIC90 for methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495425	AUC (0 to infinity) in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570689	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495535	Toxicity in human assessed as occurrence of diarrhea at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495473	Renal clearance in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495389	Toxicity in healthy human assessed as occurrence of headache at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495619	AUC (0 to 24 hrs) in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495489	Ratio of fAUC to MIC90 for Penicillin-sensitive Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495396	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495434	Cmax in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571120	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571872	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495393	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495395	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570684	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495444	Tmax in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571121	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495458	Terminal volume of distribution in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495426	AUC (0 to infinity) in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571385	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495614	AUC (0 to last) in human at 75 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571576	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495576	AUC (0 to last) in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495449	Terminal phase elimination half-life in healthy human at 250 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495543	Toxicity in human assessed as occurrence of somnolence at 750 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570904	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495451	Terminal phase elimination half-life in healthy human at 1000 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571837	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495454	Terminal volume of distribution in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571840	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495536	Toxicity in human assessed as occurrence of diarrhea at 750 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571145	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571144	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495546	Cmax in human at 250 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570666	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571875	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495534	Toxicity in human assessed as occurrence of diarrhea at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570680	Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Streptococcus pneumoniae	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495542	Toxicity in human assessed as occurrence of somnolence at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571835	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495418	Toxicity in healthy human assessed as occurrence of ear pain at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495492	Ratio of fAUC to MIC90 for ciprofloxacin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571384	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495374	Toxicity in healthy human assessed as occurrence of pruritus at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495457	Terminal volume of distribution in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495462	Clearance in healthy human at 125 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495376	Toxicity in healthy human assessed as occurrence of erythema at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571375	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571846	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495370	Toxicity in healthy human assessed as occurrence of pruritus at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495446	Terminal phase elimination half-life in healthy human at 25 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495580	Terminal half life in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570686	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495491	Ratio of fAUC to MIC90 for penicillin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571349	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571367	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570930	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495618	AUC (0 to last) in human at 750 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571151	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495524	Toxicity in human assessed as occurrence of rashes at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570709	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571350	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495522	Toxicity in human assessed as occurrence of dermatitis at 750 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495597	Oral clearance in human at 500 mg/kg measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495464	Clearance in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495373	Toxicity in healthy human assessed as occurrence of pruritus at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495406	Toxicity in healthy human assessed as occurrence of pustular rashes at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495466	Clearance in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571865	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495525	Toxicity in human assessed as occurrence of rashes at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571376	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495568	Tmax in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495423	Toxicity in healthy human assessed as occurrence of ear pain at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495397	Toxicity in healthy human assessed as occurrence of abdominal pain at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571871	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495443	Tmax in healthy human at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571876	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571374	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571140	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571372	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495485	Antimicrobial activity against ciprofloxacin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495579	Terminal half life in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495540	Toxicity in human assessed as occurrence of pollakiuria at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571354	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495490	Ratio of fAUC to MIC90 for penicillin-intermediate Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571362	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495415	Toxicity in healthy human assessed as occurrence of nausea at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495377	Toxicity in healthy human assessed as occurrence of erythema at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570888	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495565	Tmax in human at 750 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571368	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571383	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495404	Toxicity in healthy human assessed as occurrence of pustular rashes at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495550	Cmax in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495487	Antimicrobial activity against methicillin-resistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571851	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495382	Toxicity in healthy human assessed as occurrence of erythema at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495564	Tmax in human at 500 mg/kg, po measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495486	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495453	Terminal volume of distribution in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571379	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495590	Clearance in human assessed as compound recovered in urine at 750 mg/kg, po measured on day 10 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495519	Toxicity in human assessed as incidence of headache at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495587	Clearance in human assessed as compound recovered in urine at 500 mg/kg, po measured on day 10 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570897	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571355	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495620	AUC (0 to last) in human at 1000 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570670	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495561	Tmax in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495430	AUC (0 to infinity) in healthy human at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495392	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495448	Terminal phase elimination half-life in healthy human at 125 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571854	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570669	Antibacterial activity against Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495414	Toxicity in healthy human assessed as occurrence of nausea at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495520	Toxicity in human assessed as occurrence of dermatitis at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495390	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571109	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495547	Cmax in human at 500 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495467	Renal clearance in healthy human at 25 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571346	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495552	Cmax in human at 750 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570673	Antibacterial activity against Enterobacteriaceae by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571147	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495558	Tmax in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570677	Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495470	Renal clearance in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571146	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495541	Toxicity in human assessed as occurrence of somnolence at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570691	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571861	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 256 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495479	Clearance in healthy human assessed as recovery of unchanged drug in urine at 1000 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571378	Antibacterial activity against Klebsiella oxytoca assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495606	Renal clearance in human at 500 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571352	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571112	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570704	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570695	Antibacterial activity against Proteus mirabilis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495447	Terminal phase elimination half-life in healthy human at 50 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495379	Toxicity in healthy human assessed as occurrence of erythema at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570889	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495592	Clearance in human assessed as compound recovered in urine at 1000mg/kg, po measured on day 10 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495496	Ratio of fCmax to MIC90 for penicillin-sensitive Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495411	Toxicity in healthy human assessed as occurrence of nausea at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571857	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495407	Toxicity in healthy human assessed as occurrence of pustular rashes at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495554	Cmax in human at 1000 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570682	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495381	Toxicity in healthy human assessed as occurrence of erythema at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571868	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570922	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495608	Renal clearance in human at 500 mg/kg, po measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495548	Cmax in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571856	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495531	Toxicity in human assessed as occurrence of pruritus at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495477	Clearance in healthy human assessed as recovery of unchanged drug in urine at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571873	Antibacterial activity against Stenotrophomonas maltophilia assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495475	Clearance in healthy human assessed as recovery of unchanged drug in urine at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495402	Toxicity in healthy human assessed as occurrence of abdominal pain at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495616	AUC (0 to last) in human at 250 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495593	Oral clearance in human at 75 mg/kg measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495372	Toxicity in healthy human assessed as occurrence of pruritus at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495459	Terminal volume of distribution in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570902	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570674	Antibacterial activity against Pseudomonas aeruginosa by CLSI M7-A7 broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570692	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495412	Toxicity in healthy human assessed as occurrence of nausea at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571142	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571369	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495461	Clearance in healthy human at 50 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570679	Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for Staphylococcus epidermidis	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495438	Cmax in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570919	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570931	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495626	Oral clearance in human at 750 mg/kg measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495527	Toxicity in human assessed as occurrence of abdominal pain at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571364	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495368	Toxicity in healthy human assessed as occurrence of contact dermatitis at 1500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495363	Toxicity in healthy human assessed as occurrence of contact dermatitis at 250 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570681	Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for penicillin-resistant Streptococcus pneumoniae	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570698	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495549	Cmax in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571855	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571341	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495385	Toxicity in healthy human assessed as occurrence of headache at 125 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570678	Ratio of fAUC (0 to 24 hrs) in in vitro PK/PD model at 750 mg to MIC for community-associated methicillin-resistant Staphylococcus aureus	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571119	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570908	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570693	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495445	Tmax in healthy human at 1500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495478	Clearance in healthy human assessed as recovery of unchanged drug in urine at 500 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571104	Antibacterial activity against methicillin-susceptible Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571373	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 8 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495365	Toxicity in healthy human assessed as occurrence of contact dermatitis at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495609	Renal clearance in human at 750 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571858	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495581	Terminal half life in human at 250 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495595	Oral clearance in human at 250 mg/kg measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495560	AUC (0 to last) in human at 500 mg/kg, po measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID570915	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.015 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571110	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495571	AUC (0 to 24 hrs) in human at 250 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571131	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.03 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495493	Ratio of fAUC to MIC90 for methicillin-sensitive Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495456	Terminal volume of distribution in healthy human at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495409	Toxicity in healthy human assessed as occurrence of pustular rashes at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495391	Toxicity in healthy human assessed as occurrence of oral hypoesthesia at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID570703	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571386	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495484	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571387	Antibacterial activity against Enterobacter cloacae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 1 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570890	Antibacterial activity against Levofloxacin-susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571337	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.12 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495452	Terminal phase elimination half-life in healthy human at 1500 mg/kg, po administered single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571859	Antibacterial activity against Pseudomonas aeruginosa assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495369	Toxicity in healthy human assessed as occurrence of pruritus at 25 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495416	Toxicity in healthy human assessed as occurrence of nausea at 1000 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495624	AUC (0 to last) in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495582	Clearance in human assessed as compound recovered in urine at 75 mg/kg, po measured on day 1 up to 24 hrs post dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495362	Toxicity in healthy human assessed as occurrence of contact dermatitis at 500 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID571132	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495539	Toxicity in human assessed as occurrence of pollakiuria at 250 mg/kg, po administered as single dose	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571117	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of <=0.008 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495628	Ratio of fAUC (0 to 24 hrs) to MIC90 for Streptococcus pneumoniae	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571360	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 64 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570911	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID570903	Antibacterial activity against non-levofloxacin susceptible Staphylococcus aureus assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 32 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571143	Antibacterial activity against Enterococcus faecalis assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495622	AUC (0 to 24 hrs) in human at 500 mg/kg, po measured on day 16	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571377	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 128 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571122	Antibacterial activity against Streptococcus pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.25 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495613	AUC (0 to 24 hrs) in human at 75 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571371	Antibacterial activity against Klebsiella pneumoniae assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 2 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID495384	Toxicity in healthy human assessed as occurrence of headache at 50 mg/kg, po	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
AID495545	Cmax in human at 75 mg/kg, po measured on day 1	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495563	Tmax in human at 500 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID495555	Cmax in human at 1000 mg/kg, po measured on day 10	2010	Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1	Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers.
AID571336	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.06 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571356	Antibacterial activity against Escherichia coli assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 4 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571877	Antibacterial activity against Acinetobacter baumannii assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 0.5 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
AID571344	Antibacterial activity against Enterococcus faecium assessed as percent cumulative susceptible isolates at minimum inhibitory concentration of 16 ug/ml by CLSI broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (7.69)	29.6817
2010's	30 (76.92)	24.3611
2020's	6 (15.38)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.91

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	40.91 (24.57)
Research Supply Index	4.03 (2.92)
Research Growth Index	4.94 (4.65)
Search Engine Demand Index	57.52 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (40.91)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	15 (37.50%)	5.53%
Reviews	4 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	1 (2.50%)	0.25%
Other	20 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP [NCT02205112]	Phase 3	598 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as t [NCT03362853]	Phase 1	48 participants (Actual)	Interventional	2012-06-25	Completed
A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration With Nemonoxacin in Treating Elderly Patients With Community-Acquired Pneumonia [NCT05133752]	Phase 4	100 participants (Actual)	Interventional	2018-09-11	Completed
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function [NCT02604498]	Phase 1	20 participants (Actual)	Interventional	2016-04-14	Completed
Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function [NCT02840812]	Phase 1	24 participants (Anticipated)	Interventional	2017-04-05	Recruiting
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens [NCT00685698]	Phase 2	40 participants (Actual)	Interventional	2008-06-30	Completed
Phase I Clinical Study on Oral Nemonoxacin Malate Capsules [NCT01395108]	Phase 1	76 participants (Actual)	Interventional	2008-01-31	Completed
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT00434291]	Phase 2	264 participants (Anticipated)	Interventional	2006-12-31	Completed
A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01529476]	Phase 3	540 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion [NCT01529957]	Phase 1	176 participants (Actual)	Interventional	2008-09-30	Completed
A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) [NCT01537250]	Phase 2	192 participants (Actual)	Interventional	2009-08-31	Completed
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP) [NCT01944774]	Phase 2	207 participants (Actual)	Interventional	2013-03-31	Completed
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia [NCT03551210]	Phase 3	342 participants (Actual)	Interventional	2016-05-04	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00685698 (19) [back to overview]	Clinical Success (at End of Treatment/Early Termination)
NCT00685698 (19) [back to overview]	Clinical Success (in ITT Population)
NCT00685698 (19) [back to overview]	Clinical Success (in PP Population)
NCT00685698 (19) [back to overview]	Microbiological Success Rate
NCT00685698 (19) [back to overview]	Total Wound Score (at End of Treatment/ Early Termination in ITT Population)
NCT00685698 (19) [back to overview]	Total Wound Score (at End of Treatment/ Early Termination in PP Population)
NCT00685698 (19) [back to overview]	Total Wound Score (at Test of Cure in ITT Population)
NCT00685698 (19) [back to overview]	Total Wound Score (at Test of Cure in PP Population)
NCT00685698 (19) [back to overview]	Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population
NCT00685698 (19) [back to overview]	Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population
NCT00685698 (19) [back to overview]	Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population
NCT00685698 (19) [back to overview]	Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population
NCT00685698 (19) [back to overview]	Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
NCT00685698 (19) [back to overview]	Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)
NCT00685698 (19) [back to overview]	Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
NCT00685698 (19) [back to overview]	Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)
NCT00685698 (19) [back to overview]	Per-Pathogen Clinical Response (at End of Treatment/Early Termination)
NCT00685698 (19) [back to overview]	Per-Pathogen Clinical Responses (at Test of Cure)
NCT00685698 (19) [back to overview]	Per-Pathogen Microbiological Responses
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the CE Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the mITT Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the Clinically Evaluable (CE) Population
NCT01944774 (12) [back to overview]	Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number for Microbiologically Cured and Failure at Visit 4 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 3 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 3 in BE (Bacteriological Evaluable) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 4 in b-mITT (Bacteriological mITT) Population
NCT01944774 (12) [back to overview]	Subject Number of Success and Failure in Overall Efficacy at Visit 4 in BE (Bacteriological Evaluable) Population
NCT03551210 (10) [back to overview]	Number of Patients Required for Other Antibiotic Treatment
NCT03551210 (10) [back to overview]	Number of Patients With Infection Relapse
NCT03551210 (10) [back to overview]	Terminal Elimination Half-life (T1/2) of Nemonoxacin
NCT03551210 (10) [back to overview]	Time to Switch Therapy From Intravenous to Oral Therapy
NCT03551210 (10) [back to overview]	Volume of Distribution at Steady State (Vss) of Nemonoxacin
NCT03551210 (10) [back to overview]	Сlearance (CL) of Nemonoxacin
NCT03551210 (10) [back to overview]	Area Under the Concentration-time Curve (AUC) of Nemonoxacin
NCT03551210 (10) [back to overview]	Nemnoxacin Concentration Changes
NCT03551210 (10) [back to overview]	Number of Patients With Microbiological Success
NCT03551210 (10) [back to overview]	Number of Patients With Clinical Success as Judged by the Investigator

Clinical Success (at End of Treatment/Early Termination)

"Clinical Success~Resolution is defined as total resolution of all pretreatment clinically significant signs and symptoms of infection and no development of any systemic evidence of infection.~Improvement is defined as resolution of more than two, but not all, pretreatment clinical signs and symptoms, or partial resolution of all clinical signs and symptoms relative to the baseline assessment, with no further need for antibiotic therapy, and no need for infection-related surgical interventions." (NCT00685698)
Timeframe: End of Treatment/Early Termination Visit; 7±1, 14±1, 21±1 or 28±1 days after Baseline (Day 1)

Intervention	percentage of participants (Number)
Nemonoxacin (ITT Population at EOT/ET)	100.0
Nemonoxacin (PP Population at EOT/ET)	100.0

Intervention	percentage of participants (Number)
Nemonoxacin (ITT Population at Test of Cure Visit)	82.6
Nemonoxacin (PP Population at Test of Cure Visit)	89.5

Intervention	scores on a scale (Mean)
Nemonoxacin (at Baseline, ITT Population)	16.9
Nemonoxacin (at EOT/ET Visit, ITT Population)	7.2
Nemonoxacin (Change From Baseline to EOT/ET Visit)	-9.6

Intervention	scores on a scale (Mean)
Nemonoxacin (at Baseline, PP Population)	18.2
Nemonoxacin (at EOT/ET Visit, PP Population)	6.2
Nemonoxacin (Change From Baseline to EOT/ET Visit)	-12.1

Intervention	scores on a scale (Mean)
Nemonoxacin (at Baseline, ITT Population)	16.9
Nemonoxacin (at Test of Cure Visit, ITT Population)	6.0
Nemonoxacin (Change From Baseline to Test of Cure Visit)	-11.2

Intervention	scores on a scale (Mean)
Nemonoxacin (at Baseline, PP Population)	18.2
Nemonoxacin (at Test of Cure Visit, PP Population)	5.0
Nemonoxacin (Change From Baseline to Test of Cure Visit)	-12.9

Intervention	participants (Number)
	Uninfected to Uninfected	Uninfected to Mild	Uninfected to Moderate	Uninfected to Severe	Mild to Uninfected	Mild to Mild	Mild to Moderate	Mild to Severe	Moderate to Uninfected	Moderate to Mild	Moderate to Moderate	Moderate to Severe	Severe to Uninfected	Severe to Mild	Severe to Moderate	Severe to Severe
Nemonoxacin	0	0	0	0	8	4	0	0	12	5	3	0	0	0	0	0

Intervention	participants (Number)
	Surgery Required for DFI During Study	Hospitalisation Required for DFI During Study	New or Additional Antibiotic Therapy Required
Nemonoxacin	1	1	3

Intervention	percentage of participants (Number)
	Staphylococcus aureus (in ITT population)	Escherichia coli (in ITT population)	Enterococcus faecalis (in ITT population)	Streptococcus agalactiae (in ITT population)	Streptococcus pyogenes (in ITT population)
Nemonoxacin (ITT Population at EOT/ET)	100.0	100.0	100.0	100.0	100.0
Nemonoxacin (PP Population at EOT/ET)	100.0	100.0	100.0	100.0	NA

Intervention	percentage of participants (Number)
	Staphylococcus aureus	Escherichia coli (in ITT population)	Enterococcus faecalis (in ITT population)	Streptococcus agalactiae (in ITT population)	Streptococcus pyogenes (in ITT population)
Nemonoxacin (ITT Population at Test of Cure Visit)	100.0	100.0	100.0	100.0	100.0
Nemonoxacin (PP Population at Test of Cure Visit)	100.0	100.0	100.0	100.0	NA

Intervention	participants (Number)
	Success	Fail	Not evaluable
Moxifloxacin 400 mg	56	2	2
Nemonoxacin 500 mg	58	4	1
Nemonoxacin 650 mg	56	3	0

Intervention	participants (Number)
	Success	Failure	Not evaluable
Moxifloxacin 400 mg	16	0	1
Nemonoxacin 500 mg	22	2	0
Nemonoxacin 650 mg	18	1	0

Intervention	participants (Number)
	Success	Failure	Unevaluable
Moxifloxacin 400 mg	15	1	1
Nemonoxacin 500 mg	22	2	0
Nemonoxacin 650 mg	17	2	0

Intervention	Participants (Count of Participants)
	Visit 272195661			Visit 272195662	Visit 372195662	Visit 372195661
	Clinical success	Clinical non-efficacy	Indefinite response
Nemonoxacin	164
Tavanic®	154
Nemonoxacin	4
Tavanic®	5
Nemonoxacin	1
Nemonoxacin	160
Tavanic®	151
Nemonoxacin	6
Tavanic®	7
Nemonoxacin	3
Tavanic®	8

Substance	Relationship Strength	Studies	Trials	Classes	Roles
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	8.51	1	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	2.76	3	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	2.05	1	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	9.76	2	1	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	8.51	1	1	benzoic acids; sulfonamide	uricosuric drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	2.13	1	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	13.66	38	15	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
limestone Calcium Carbonate: Carbonic acid calcium salt (CaCO3). An odorless, tasteless powder or crystal that occurs in nature. It is used therapeutically as a phosphate buffer in hemodialysis patients and as a calcium supplement.. calcium carbonate : A calcium salt with formula CCaO3.	3.48	1	1	calcium salt; carbonate salt; inorganic calcium salt; one-carbon compound	antacid; fertilizer; food colouring; food firming agent
ferrous sulfate ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.	8.48	1	1	iron molecular entity; metal sulfate	reducing agent
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	2.05	1	0	penicillin allergen; penicillin	antibacterial drug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	2.1	1	0	cephalosporin	fungal metabolite
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	7.06	1	0	carbapenems
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.05	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
garenoxacin garenoxacin: a des-fluoro(6) quinolone with antibacterial activity. garenoxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid that is substituted by a cyclopropyl group at position 1, an oxo group at position 4, a (1R)-1-methyl-2,3-dihydro-1H-isoindol-5-yl group at position 7, and a difluoromethoxy group at position 8.	2.13	1	0	aromatic ether; cyclopropanes; isoindoles; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic	antibacterial drug; non-steroidal anti-inflammatory drug
carbapenems [no description available]	2.06	1	0
beta-lactams 2-azetidinone: structure in first source. azetidin-2-one : An unsubstituted beta-lactam compound.. beta-lactam : A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.	2.06	1	0	beta-lactam antibiotic allergen; beta-lactam
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	8.98	8	4	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	7.06	1	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	3.21	5	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	7.06	1	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
abt 492 WQ 3034: structure in first source	3.23	1	0
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	7.46	2	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
zabofloxacin zabofloxacin: a fluoroquinolone antibiotic	8.23	1	0
finafloxacin finafloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, 7 and 8 by cyclopropyl, fluoro, hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl and cyano groups respectively; an antibiotic used for treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.	8.23	1	0	cyclopropanes; monocarboxylic acid; nitrile; organofluorine compound; quinolone; secondary amino compound; tertiary amino compound	antibacterial drug; antimicrobial agent
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	2.75	3	0
tigecycline [no description available]	2.75	3	0
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	7.1	1	0	cephalosporin; thiadiazoles	antimicrobial agent

Condition	Indicated	Relationship Strength	Studies	Trials
Contact Dermatitis [description not available]	0	3.44	1	1
Bilateral Headache [description not available]	0	3.44	1	1
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	0	3.44	1	1
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	3.44	1	1
Community Acquired Infection [description not available]	0	8.61	7	3
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	7.64	6	2
Pulmonary Consumption [description not available]	0	2.41	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	1	9.64	6	2
Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung.	0	2.41	1	0
Disease Exacerbation [description not available]	0	2.6	1	0
Airflow Obstruction, Chronic [description not available]	0	2.6	1	0
Pulmonary Disease, Chronic Obstructive A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.	0	2.6	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.25	1	0
Blood Poisoning [description not available]	0	2.25	1	0
Innate Inflammatory Response [description not available]	0	2.25	1	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.25	1	0
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	0	7.25	1	0
Electrocardiogram QT Prolonged [description not available]	0	4.48	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	0	4.48	1	1
Bacterial Pneumonia [description not available]	0	7.28	4	2
Pneumonia, Bacterial Inflammation of the lung parenchyma that is caused by bacterial infections.	1	9.28	4	2
Disease, Pulmonary [description not available]	0	3.59	1	1
Lung Diseases Pathological processes involving any part of the LUNG.	0	3.59	1	1
Liver Dysfunction [description not available]	0	4.51	1	1
Liver Diseases Pathological processes of the LIVER.	1	6.51	1	1
Infections, Pneumococcal [description not available]	0	2.08	1	0
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	0	2.08	1	0
Infections, Staphylococcal [description not available]	0	2.5	2	0
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	0	2.5	2	0
Diabetic Feet [description not available]	0	3.01	1	0
Bacterial Disease [description not available]	0	3.01	1	0
Bacterial Infections Infections by bacteria, general or unspecified.	1	5.01	1	0
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	0	3.01	1	0
Infections, Chlamydia [description not available]	0	3.03	1	0
Clostridioides difficile Infection [description not available]	0	3.03	1	0
Neisseria gonorrhoeae Infection [description not available]	0	3.03	1	0
Bacterial Skin Diseases [description not available]	0	3.03	1	0
Chlamydia Infections Infections with bacteria of the genus CHLAMYDIA.	0	3.03	1	0
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	0	3.03	1	0
Gonorrhea Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.	0	3.03	1	0
Skin Diseases, Bacterial Skin diseases caused by bacteria.	0	3.03	1	0
Koch's Disease [description not available]	0	2.05	1	0
Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.	0	7.05	1	0
Bacterial Infections, Gram-Positive [description not available]	0	2.46	2	0
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	0	2.46	2	0
Infections, Helicobacter [description not available]	0	2.05	1	0
Helicobacter Infections Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.	0	2.05	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.05	1	0
Bacterial Infections, Gram-Negative [description not available]	0	2.05	1	0
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	0	2.05	1	0
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	2.05	1	0
Cronobacter Infections [description not available]	0	2.06	1	0
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	0	2.06	1	0
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	3.46	1	1

chemdatabank.com

nemonoxacin

Description

Cross-References

Synonyms (26)

Research Excerpts

Overview

Effects

Actions

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Bioassays (438)

Research

Studies (39)

Market Indicators

Research Demand Index: 40.91

Study Types

Clinical Trials (13)

Trial Overview

Trial Outcomes

Clinical Success (at End of Treatment/Early Termination)

Clinical Success (in ITT Population)

Clinical Success (in PP Population)

Microbiological Success Rate

Total Wound Score (at End of Treatment/ Early Termination in ITT Population)

Total Wound Score (at End of Treatment/ Early Termination in PP Population)

Total Wound Score (at Test of Cure in ITT Population)

Total Wound Score (at Test of Cure in PP Population)

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in ITT Population

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at End of Treatment/Early Termination in PP Population

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in ITT Population

Diabetic Foot Assessment (PEDIS) Shifts From Baseline at Test of Cure in PP Population

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in ITT Population)

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)

Need for Surgery, Hospitalisation and Non-Study Antibiotic Therapy for Diabetic Foot Infection During Study (in PP Population)

Per-Pathogen Clinical Response (at End of Treatment/Early Termination)

Per-Pathogen Clinical Responses (at Test of Cure)

Per-Pathogen Microbiological Responses

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the CE Population

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 3 in the mITT Population

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the Clinically Evaluable (CE) Population

Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population

Subject Number for Microbiologically Cured and Failure at Visit 3 in b-mITT (Bacteriological mITT) Population

Subject Number for Microbiologically Cured and Failure at Visit 3 in BE (Bacteriological Evaluable) Population

Subject Number for Microbiologically Cured and Failure at Visit 4 in b-mITT (Bacteriological mITT) Population

Subject Number for Microbiologically Cured and Failure at Visit 4 in BE (Bacteriological Evaluable) Population

Subject Number of Success and Failure in Overall Efficacy at Visit 3 in b-mITT (Bacteriological mITT) Population

Subject Number of Success and Failure in Overall Efficacy at Visit 3 in BE (Bacteriological Evaluable) Population

Subject Number of Success and Failure in Overall Efficacy at Visit 4 in b-mITT (Bacteriological mITT) Population

Subject Number of Success and Failure in Overall Efficacy at Visit 4 in BE (Bacteriological Evaluable) Population

Number of Patients Required for Other Antibiotic Treatment

Number of Patients With Infection Relapse

Terminal Elimination Half-life (T1/2) of Nemonoxacin

Time to Switch Therapy From Intravenous to Oral Therapy

Volume of Distribution at Steady State (Vss) of Nemonoxacin

Сlearance (CL) of Nemonoxacin

Area Under the Concentration-time Curve (AUC) of Nemonoxacin

Nemnoxacin Concentration Changes

Number of Patients With Microbiological Success

Number of Patients With Clinical Success as Judged by the Investigator

Related Drugs (27)

Related Conditions (54)